Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2015 1
2016 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.
Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vinereanu D, Hamid MA, Jourdain P, Ponikowski P. Lopatin YM, et al. Int J Cardiol. 2016 Jan 15;203:909-15. doi: 10.1016/j.ijcard.2015.11.060. Epub 2015 Nov 7. Int J Cardiol. 2016. PMID: 26618252 Review.
Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. ...This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failu
Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. ...This r
Current Clinical Evidence of Trimetazidine in the Management of Heart Disease in Patients with Diabetes.
Mahajan S, Mahajan AU. Mahajan S, et al. J Assoc Physicians India. 2020 Nov;68(11):46-50. J Assoc Physicians India. 2020. PMID: 33187037 Review.
Therefore, there is a need for early and effective treatment intervention for this myocardial cell metabolic dysfunction. DM and myocardial ischemia (MI) share a common metabolic dysregulation mediated via increased fatty acid oxidation that makes the …
Therefore, there is a need for early and effective treatment intervention for this myocardial cell metabolic dysfunction. DM a …
The role of trimetazidine after acute myocardial infarction.
Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. Banach M, et al. Curr Vasc Pharmacol. 2008 Oct;6(4):282-91. doi: 10.2174/157016108785909788. Curr Vasc Pharmacol. 2008. PMID: 18855716 Review.
Trimetazidine is the most investigated drugs in this group. The ESC 2006 guidelines on the management of patients with stable angina mention the efficacy of metabolic treatment in improving physical efficiency and decreasing the recurrence of pain. ...The mos
Trimetazidine is the most investigated drugs in this group. The ESC 2006 guidelines on the management of patients with stable
["Persistent" angina: rationale for a metabolic approach].
Marzilli M. Marzilli M. Ital Heart J. 2004 Mar;5 Suppl 2:37S-41S. Ital Heart J. 2004. PMID: 15074776 Review. Italian.
Significant progress has been made in recent years in understanding the role of cardiac energy metabolism in the pathogenesis of myocardial ischemia. A better understanding of metabolic derangements associated with ischemia and reperfusion is translating into …
Significant progress has been made in recent years in understanding the role of cardiac energy metabolism in the pathogenesis of m